CAD and neoplasm: In the new era, biomarkers such as CPS, deficient mismatch repair/MSI-high (dMMR/MSI-H), and tumor mutation burden will be essential for selecting effective perioperative chemotherapy regimens, whether chemotherapy or ICIs [41].